Study on the Safety and Effects of a Combined IV Treatment with Tiragolumab and Atezolizumab for Advanced Solid Tumors

Inclusion Criteria

• Be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of at least 12 weeks.
• Have good blood and organ function.
• Have recovered from any side effects of previous treatments, except for hair loss.
• Women of childbearing potential must have a negative pregnancy test before starting the study and agree to use effective birth control during the study and for 5 months after the last dose.
• Men must agree to use condoms or abstain from intercourse and refrain from donating sperm during the study and for 90 days after the last dose.

Cancer-Specific Inclusion Criteria:

• Have a confirmed diagnosis of advanced, recurrent, or metastatic cancer that cannot be treated with local therapy, and for which this study treatment is considered an option.
• Have not received prior treatment with checkpoint inhibitors.
• Have measurable disease according to specific criteria.
• Provide a tumor sample for PD-L1 evaluation before joining the study.
• Have tumors selected based on PD-L1 testing.

Exclusion Criteria

• Women who are pregnant or breastfeeding, or planning to become pregnant during the study or within 5 months after the last dose.
• Have significant heart disease.
• Have serious liver disease.
• Have poorly controlled Type 2 diabetes.
• Have had major surgery within 28 days before starting the study or need major surgery during the study.
• Have any other serious health conditions that could interfere with the study or increase risk.
• Have a history of autoimmune disease.
• Have used systemic immunosuppressive medications within 2 weeks before starting the study.
• Have a history of lung diseases like pulmonary fibrosis or pneumonitis.
• Have had severe infections recently or needed antibiotics within 2 weeks before starting the study.

Cancer-Specific Exclusion Criteria:

• Have received any anti-cancer treatment within 3 weeks before starting the study.
• Have been treated with immune checkpoint inhibitors before.
• Have not waited long enough after previous treatments with certain drugs or therapies before starting the study.
• Have had severe immune-related side effects from previous cancer treatments that have not fully resolved.